Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05348694

OsteoPreP: Food Supplements for Postmenopausal Bone Health

Conditions: Postmenopausal Osteopenia, Bone Loss, Age Related, Age-Related Sarcopenia, Glucose Metabolism Disorders, Age-related Cognitive Decline

Sex: Female
Ages: 40 Years – 65 Years
Healthy volunteers: Yes
Phase: PHASE4
Enrollment: 160
Sponsor: Australian Catholic University

Location: Australian Catholic University Melbourne Victoria

Summary

To evaluate the effect of 12 months of supplementation with a probiotic (probiotic plus prebiotic; 2 capsules per day) on relative change (%) in total volumetric bone density (measured using high resolution peripheral quantitative computed tomography \[HR-pQCT\]) of the distal tibia.

Eligibility Criteria

Inclusion Criteria: * Postmenopausal women, 40-65 years old * Caucasian (due to significant differences in BMD and bone remodelling between ethnicities) * At least one year since final menses * Signed informed consent * Up to date Covid 19 vaccination status * Able to walk without the use of an aid * Stated availability throughout the entire study period * Mental capacity to understand and willingness to fulfil all the details of the protocol * Residing in Melbourne, Victoria, Australia Exclusion Criteria: * Diagnosis of osteoporosis * T-score of -2.5 or less at the femoral neck or lumbar spine (L1-L4) on the DXA scan at screening visit * HbA1c ≥6.5% at screening visit * Blood pressure at screening visit of systolic \>180 mmHg and/or diastolic \>120 mmHg * Untreated hyperthyroidism * Rheumatoid arthritis * Diagnosed with a disease-causing secondary osteoporosis or malabsorption: chronic obstructive pulmonary disease, inflammatory bowel disease, celiac disease, type 1/type 2 diabetes, or chronic liver disease * Bariatric surgery * Recently diagnosed malignancy (within the last 5 years) * Current or recent oral corticosteroid use (any dose within the last 3 months, or 5mg of Prednisolone (or equivalent) or a higher daily dose for 14 days or more 3-12 months prior to screening) * Use of antiresorptive therapy, including systemic hormone replacement therapy, bisphosphonates, strontium ranelate (current or during the last 3 years) * Use of teriparatide (current or during the last 3 years) * Participation in other clinical intervention trials * Antibiotics treatment 2 months prior to inclusion * Unwilling to cease taking other probiotic or prebiotic supplements (current use)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05348694). StuddyBuddy aggregates publicly available trial information.